Skip to main content
Pharma merger to focus on gene therapy development for rare diseases

Inotek Pharmaceuticals and Rocket Pharmaceuticals will merge to advance its product pipeline involving adeno-associated virus and lentiviral virus gene therapies with a special focus on rare diseases, such as Rocket's LVV treatments for bone marrow diseases caused by gene mutations. Rocket shareholders will own about 81% of the new firm, and the remaining 19% will be owned by Inotek shareholders.

Full Story: